Zura Bio (NASDAQ:ZURA) Receives Neutral Rating from HC Wainwright

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 110.08% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital decreased their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Finally, Leerink Partners initiated coverage on shares of Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $15.80.

Zura Bio Stock Up 4.4 %

NASDAQ ZURA opened at $2.38 on Tuesday. The firm’s fifty day moving average price is $3.55 and its 200 day moving average price is $3.68. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Equities analysts anticipate that Zura Bio will post -0.65 EPS for the current year.

Insiders Place Their Bets

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 22.10% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares during the last quarter. Renaissance Technologies LLC raised its position in Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. Great Point Partners LLC raised its position in Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after acquiring an additional 1,884,501 shares during the last quarter. Armistice Capital LLC lifted its holdings in shares of Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Zura Bio in the second quarter valued at approximately $43,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.